Ansel Hillmer, PhD, and Eric Webb, PhD, have received a $100,000 SNMMI grant for developing a novel PET radiotracer targeting brain inflammation in Alzheimer's disease.
Key Details
- 1Awarded the $100,000 Drs. Jane & Abass Alavi Mars Shot Research Award from SNMMI's 2026 fund.
- 2Research targets colony stimulating factor 1 receptor (CSF1R) as a novel inflammation marker in Alzheimer’s.
- 3Project focuses on developing and validating 18F-PLX5622 as a PET radiotracer.
- 4Initial studies will use mouse models; human tissue validation will follow.
- 5The aim is to enable CSF1R imaging for diagnosis, monitoring, and potential treatment guidance in Alzheimer’s patients.
- 6SNMMI Mars Shot Fund established in 2023 to support visionary nuclear imaging research.
Why It Matters
This research could lead to significant advances in the imaging and understanding of brain inflammation in Alzheimer’s disease, enabling better diagnosis and targeted therapy. It also demonstrates ongoing innovation in PET radiotracer development for neurodegenerative disorders.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.